A Prescription Drug User Fee Act target date of June 20, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics ...

DEAR DR. ROACH: I have had an autoimmune disease called bullous pemphigoid for the past four years. I originally was treated with prednisone therapy for over a year, which was then tapered and changed ...

Trial met the primary and all key secondary endpoints in adults with moderate-to-severe disease; five times more patients achieved sustained disease remission with Dupixent than placebo Dupixent is ...

The U.S. Food and Drug Administration (FDA) on Friday approved Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Sanofi SA’s (NASDAQ:SNY) Dupixent (dupilumab) for adult patients with bullous pemphigoid ...

Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study Study met the primary and all key secondary ...

“Bullous pemphigoid is a debilitating skin disease with a high mortality rate due to infection. Dupixent is the first medication to show significant and robust impacts in this patient population.

Findings showed 20% of patients treated with dupilumab experienced sustained disease remission at week 36 compared with 4% of those who received placebo. Treatment with dupilumab led to significant ...

“Bullous pemphigoid is a debilitating skin disease with a high mortality rate due to infection. Dupixent is the first medication to show significant and robust impacts in this patient population,” ...